Objectives: To clarify the incidence rate of post-transplant diabetes mellitus and associated risk factors in Japanese kidney transplant recipients, and to explore which treatment components are most effective in reducing post-transplant diabetes mellitus. Methods: We analyzed 849 Japanese non-diabetic adult recipients who had undergone living kidney transplantation and had received tacrolimus-based immunosuppression from 1996 to 2013 with a median follow-up of 5 years. Results: In all, 127 patients developed post-transplant diabetes mellitus during the follow-up period. The incidence rate of post-transplant diabetes mellitus was 15.1% (95% confidence interval 12.7-17.5) at 5 years. Recipient age (hazard ratio 1.05, 95% confidence interval 1.05-1.06, P < 0.001 for every 5-year increase), obesity (hazard ratio 1.70, 95% confidence interval 1.06-2.73, P = 0.028), tacrolimus trough level at 2 weeks post-transplantation (hazard ratio 1.06, 95% confidence interval 1.03-1.09, P < 0.001 for a 1-ng/mL increase) and mycophenolate mofetil use (hazard ratio 0.46, 95% confidence interval 0.28-0.77, P = 0.003) were significant predictors of post-transplant diabetes mellitus. Estimated 5-year predicted incidence rate after adjusting for age and obesity was 9.4% for recipients with a low tacrolimus trough level, and receiving mycophenolate mofetil and 38.4% for recipients with a high tacrolimus trough level and not receiving mycophenolate mofetil. Conclusions: Post-transplant diabetes mellitus is a common complication in Japan, similar to that in other Western countries. The present results show that an appropriate immunosuppressive regimen with a combination of tacrolimus and mycophenolate mofetil can reduce the likelihood of developing post-transplant diabetes mellitus. Clinical trials are required to confirm these findings.
Introduction
KT provides superior outcomes compared with dialysis, in terms of both quantity and quality of life. 1 Although graft and patient survival rates for KTRs have improved significantly, several complications continue to adversely affect post-transplant morbidity and mortality rates. PTDM is a major and common complication, and is observed in approximately 4-25% of KTRs. PTDM affects kidney transplant outcomes, and increases the incidence of post-transplant cardiovascular disease. [2] [3] [4] Prevention of PTDM in KTRs would be preferable over intervention using insulin or oral hypoglycemic agents. [5] [6] [7] Furthermore, reducing the development of PTDM might improve long-term patient and graft outcomes. Although studies investigating PTDM after KT have been reported for Western populations, PTDM has not been well-studied in Japan. [8] [9] [10] [11] In addition, differences in the impact of two common TAC formulations on PTDM remain unclear. The aims of the present study were: (i) to clarify the PTDM incidence rate in Japanese patients who underwent living KT; (ii) to determine associated risk factors; and (iii) to explore which treatment components are most effective in reducing PTDM.
Methods

Study population
We analyzed 849 KTRs who: (i) had participated in the JACK project between 23 April 1996 and 27 December 2013; (ii) had undergone living KT; (iii) were aged 18 years or older; and (iv) had completed follow up at three transplant centers. The JACK project is an ongoing multicenter, retrospective observational cohort study in Japan. The objectives and protocol of the JACK have been previously described in great detail. 12 KTRs were excluded if they had diabetes (fasting PG level ≥126 mg/dL or 2-h PG level ≥200 mg/dL during a 75-g OGTT) at the time of KT or had ESRD caused by diabetic nephropathy. Prediabetic recipients with IFG or IGT were included in the current study. All KTRs were being treated with TAC-based immunosuppression consisting of twice-daily immediate-release or once-daily extended-release formulations. Our detailed immunosuppressive regimens at that time have also been previously reported. 13 The relevant ethics committee at each participating center approved the protocol, and all patients provided written informed consent. The JACK is registered with the University Hospital Medical Information Network (UMIN000018327).
Definitions
The end-point of the present study was the first occurrence of PTDM after KT; that is, new-onset diabetes after transplantation.
14 Pretransplant diabetes and PTDM were defined in accordance with American Diabetes Association and World Health Organization guidelines. 4 The eGFR was calculated using the CKD-EPI equation. 15 Obesity was defined as >25 kg/m BMI at transplant according to the Japan Society for the Study of Obesity guidelines. 16 The definition of acute rejection included T cell-mediated or antibody-mediated rejection, proven using episode or protocol biopsy. Overall mortality was defined as death from any cause, regardless of whether the graft was preserved or lost. TAC trough levels were measured using locally available assays.
Follow up
The final follow up was carried out on 31 March 2016, by which time the study population had accrued 3400 personyears of follow up with a median of 5 years. Patients with a follow up >5 years had their data censored at 5 years.
Statistical analysis
Analyses were carried out using SAS system version 9.4 software (SAS Institute, Cary, NC, USA). Data are presented as means with standard deviations, and medians with interquartile ranges. The cumulative probabilities of PTDM were estimated using the Kaplan-Meier method. To clarify the optimal threshold of TAC trough concentration for PTDM development, a ROC analysis with the Youden index was carried out. To identify independent risk factors associated with PTDM, a Cox proportional hazards model with the stepwise variable selection method was used. PTDM incidence rates after adjusting for confounding variables were also generated using the Cox model. The proportional hazards assumption was confirmed using log e [Àlog e (s(t))]. The influence of profile, interaction, and multicollinearity in the multivariable model were examined using a regression diagnostic and sensitivity analysis. Two-tailed P-values of <0.05 were considered statistically significant.
Results
Characteristics
Of the 849 KTRs, 127 developed PTDM during the 5-year follow-up period. Characteristics of patients with and without PTDM are provided in Table 1 . Compared with KTRs without PTDM, KTRs with PTDM were more likely to have older age, high BMI, elevated blood pressure, high triglycerides, low HDL-cholesterol levels, elevated fasting PG levels, a high proportion of IGT and an unrelated donor. Furthermore, lower eGFR throughout the study period and a trend towards a higher acute rejection rate was observed in KTRs with PTDM than in KTRs without PTDM. Table 2 presents the change of immunosuppression throughout the study period. TAC dose at 2 weeks, TAC trough levels from 2 weeks through 6 months and MP dose at 1 month after KT were significantly higher in the PTDM group than in the non-PTDM group. Conversely, the use of MMF was more frequent in KTRs without PTDM than in KTRs with PTDM. No significant group differences in basiliximab and rituximab use were observed.
Overall PTDM incidence rate Figure 1 shows the overall Kaplan-Meier estimates with 95% CIs for PTDM development. Cumulative rates of PTDM were 12.0% (95% CI 9.8-14.2), 13.0% (95% CI 10.7-15.2), 14.4% (95% CI 12.0-16.8), and 15.1% (95% CI 12.7-17.5) at 6 months, 1, 3 and 5 years, respectively.
Risk factors for PTDM
Unadjusted and adjusted hazard ratios of potential risk factors for PTDM during the 5-year follow-up period are shown in Table 3 . Recipient age (HR 1.05, 95% CI 1.03-1.06, P < 0.001 for every 5-year age increase), obesity (HR 1.70, 95% CI 1.06-2.73, P = 0.028), TAC trough level at 2 weeks (HR 1.06, 95% CI 1.03-1.09, P < 0.001 for a 1-ng/mL increase) and use of MMF (HR 0.46, 95% CI 0.28-0.77, P = 0.003) were identified as independent factors associated with PTDM. Substantial interactions among these four factors were not detected in the regression diagnostic analysis. Table 4 presents the effects of MMF, TAC formulation and obesity on TAC trough levels, concomitant corticosteroid dose, acute rejection and PTDM development. MMF use and TAC once-daily formulation use was associated with low TAC trough levels and MP dose. In addition, use of these agents showed a statistically significant improvement in acute rejection. MMF was associated with a decreased risk of PTDM, whereas this association was not observed for oncedaily TAC. Although obesity was associated with an increased risk of PTDM, there were no substantial differences in TAC trough levels, MP dose or the proportion of acute rejection between obese and non-obese KTRs.
Change of immunosuppressive exposure levels
TAC trough level thresholds for each of the two TAC formulations
We carried out separate ROC analyses to identify the threshold of the trough level predicting PTDM development for each of the two TAC formulations, because different formulations have a heterogeneous pharmacokinetic variation in blood levels. For the twice-daily formulation, a TAC trough level at 2 weeks of 12.5 ng/mL was the optimal threshold ( Fig. 2a) , whereas for the once-daily formulation, a threshold of 10.5 ng/mL was optimal in predicting PTDM (Fig. 2b) .
Adjusted PTDM incidence rate Figure 3 shows the 5-year predicted curves for PTDM development based on MMF use and TAC trough level combinations. These curves were generated using a Cox model after adjusting for recipient age and obesity, which were identified as associated factors in the above analyses. According to these adjusted curves, KTRs with a low TAC trough level and MMF use had a PTDM incidence rate of 8.0%, 9.0%, 
Discussion
Using data from the JACK, a multicenter observational cohort study of KTRs in Japan, we found that: (i) the incidence rate of PTDM was 15.1% at 5 years and in many cases, PTDM occurred within the first several months; (ii) associated risk factors for PTDM included advanced age, obesity, a higher TAC trough level and the absence of MMF use; and (iii) it is possible that an optimized TAC + MMF combination regimen diminishes risk for PTDM development, which results from both a reduced TAC trough concentration and low corticosteroid dose. We clarified the rate and clinical future of PTDM in KTRs representing the Japanese population, which has not been previously reported. 17 Kamar et al. referred to discrepancies in PTDM rates between Europe and the USA. 18 Although it is difficult to precisely compare the studies because of differences in conditions, particularly regarding the utilized diagnosis criteria for PTDM, the incidence rate of PTDM in Japanese patients shown in the present study was similar to that for European patients. 2 In the present study, we excluded KTRs with pretransplant diabetes to estimate the rate of PTDM as "new-onset diabetes after transplantation." Currently, the number of KTRs with pre-existing diabetes is increasing worldwide. Thus, more diabetes in KTRs will be seen in actual practice. In fact, when KTRs with pre-existing diabetes were not excluded, the 5-year incidence rate was nearly one-third of the study population (data not shown).
As expected, KTRs with PTDM were more likely to have advanced age, obesity or other components of metabolic syndrome. Although diabetic parameters including fasting PG level and IGT were not selected as risk factors in the present study, these variables were significantly correlated with BMI in a regression diagnostic and sensitivity analysis. Some studies suggest that polycystic kidney confers an increased risk of PTDM; however, we could not show definitive evidence for this in the present study. 4 Further evaluation regarding this issue has been proposed in a report by Yates et al. 2 Risk factors and incidence rates of PTDM in KTRs have been well investigated in previous studies, and no novel risk factors were identified in the present study.
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Nevertheless, the present findings corroborate and extend recently reported findings in several aspects as described below.
The identified four risk factors in the present study can be considered as non-modifiable (older age) or modifiable (TAC trough level, MMF, obesity) according to a report by Pham et al. 4 Older age is an established major risk factor; however, it is non-modifiable. Thus, we focused on which treatment components are most effective in reducing PTDM. Similar to a previous study, MMF use appears to be favorable in preventing PTDM. 3 CNIs are well recognized as a major risk factor for PTDM development, which might cause PTDM by decreasing insulin secretion from pancreatic beta-cells. 2, 22 Steroid-free regimens have not been common in Japan. Nevertheless, high doses of corticosteroids are undoubtedly risky due to insulin resistance. using an optimized TAC and MMF combination regimen could reduce not only the TAC trough level, but also the corticosteroid dose (Table 4) . Consistent with other studies, we found a high TAC trough level after KT to be associated with an increased risk of PTDM. 19, 24 However, to our knowledge, there are few reports investigating the thresholds of two different TAC formulations in the prediction of PTDM development. Our results suggest that the two kinds of formulations have different threshold levels, with the once-daily formation having a lower threshold (>10.5 ng/mL) than the twice-daily formulation (>12.5 ng/mL; Fig. 2a,b) . TAC once-daily formulation use was associated with both a low trough level and low MP dose. However, the once-daily formulation was not associated with a decreased risk of PTDM (Table 4) . These findings appear to be important in optimizing immunosuppressive therapy to reduce PTDM. Our results might reflect a difference between the two formulations in pharmacokinetics and bioavailability. 25 However, further specialized research with more detailed hour-unit-based therapeutic drug monitoring would be required for a better understanding and definitive conclusion.
While the Kidney Disease: Improving Global Outcomes guidelines recommend TAC as a first-line CNI, several studies have suggested that the TAC-related risk for PTDM development is greater than that for cyclosporine. [26] [27] [28] Nevertheless, we showed that a low TAC trough with MMF combination immunosuppressive regimen has potential in decreasing the chance of PTDM development. Of note, even when the TAC trough level was high, MMF use was effective. This effect appears to be attributed in part to MMF associated with a reduced MP dose (Table 4) .
Furthermore, the present results suggest that obesity, which is a modifiable factor, has a different pathogenic mechanism from the effects of immunosuppression. However, the mechanism whereby obesity induces insulin resistance is poorly understood. In addition, there were no interactions between obesity and the other identified risk factors (age, TAC trough and MMF). Thus, separate management would be required to prevent PTDM in obese patients, including pre-and posttransplant weight control. 12 Although our definition of obesity was the same as that in a European study, 18 we identified a marked discrepancy in the definition between Japan and the USA. 12 Nevertheless, a relative higher BMI is considered to be an established risk factor, and this unique feature of obesity on PTDM development might be generalizable to KTRs in the USA.
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The present study had a number of limitations. First, an appropriate definition of PTDM is vital. 30 Our definition was in accordance with the American Diabetes Association/World Health Organization guidelines. However, although OGTT was carried out before KT, routine OGTT was not carried out at the follow-up outpatient clinics, which could not be resolved because of the retrospective nature of the study design. Second, limited multivariable adjustments could be made to the available data because of the observational nature of the study; thus, residual confounding could not be excluded. Third, risk factors at induction and the initial maintenance phase of immunosuppression was assessed based on an intension-to-treat basis. Although an association between acute rejection and PTDM was assessed in the present study, a dose-dependent effect of pulse steroid therapy could not be evaluated directly. In most cases, acute rejection was treated with pulse steroids consisting of MP, 500 mg/day for 2 days. Fourth, although there is evidence that patients with a family history of diabetes have an increased risk for PTDM, we could not collect precise information regarding family history. 2 Fifth, we could not evaluate a potential interaction between TAC and concomitant hepatitis C infection, because of the small number of infected patients. 4 Finally, the present study was not designed to clarify the association between modifying PTDM and subsequent long-term transplant failure. Additional long-term follow-up duration and adequate event numbers including graft failure, cardiovascular disease and patient death would be required to examine this issue.
In conclusion, PTDM is a common complication in Japan, similar to that in other Western countries. However, an appropriate TAC and MMF combination immunosuppressive regimen has potential in reducing the chance of PTDM development. Clinical trials are required to confirm these findings. 25.5 Fig. 3 Adjusted incidence rates for PTDM are shown. A TAC high trough was defined as >12.5 ng/mL (twice-daily formulation) and >10.5 ng/mL (once-daily formulation) based on the ROC analyses (Fig. 2) . Incidence rates for PTDM were obtained using Cox model with adjustment for recipient age and obesity.
